Interestingly, miR-17 has been identified to target enhancer of zeste homolog 1 (EZH1) and downregulates its expression, sensitizes non-small cell lung cancer cells to erlotinib (Zhang et al., 2017). This evidence concerns the gene EZH1 and non-small cell lung carcinoma.